Novo Nordisk collected DKK 83.8 billion of free cash flow in nine months, and guides to at most DKK 70 billion for the year

Through September, Novo Nordisk generated DKK 83.8 billion of free cash flow, about $12.6 billion. For the full year it guides to DKK 60 billion to 70 billion. By my subtraction, that implies free cash flow of minus DKK 14 billion to 24 billion in the fourth quarter. The release says the nine-month figure was helped by the timing of US rebate and tax payments, and by lower capital spending. A screener that annualizes the nine months shows a cash flow yield of about 9%; the guidance says 5.4%.

My Base value is $35.50 an ADR, the Bear value $20.13 and the Bull value $46.68. The price of $40.65 sits between the Base and the Bull. The quarter itself was good: adjusted operating profit rose 27% at constant exchange rates and the company raised its 2026 outlook for the third time. That outlook is still a range of -2% to +2% for both sales and adjusted operating profit, so the business is guided to stand still while the price list in its biggest market is cut. I could not find a company-specific reason for today's 1.19% decline.

Valuation route: large pharmaceutical company, valued with an existing-product cash flow model for 2027 to 2036 that includes US price cuts and the December 2032 US semaglutide patent expiry, cross-checked with a justified forward earnings multiple. The pipeline is not valued separately, because the growth path already assumes some of it succeeds. Danish kroner cash flows are discounted at 8.5% and converted at 6.66 kroner per dollar.

What Novo Nordisk is

Novo Nordisk makes semaglutide, the molecule in Ozempic, Wegovy and their pill versions, plus insulin and rare disease drugs. In the first nine months of 2026, Ozempic, Wegovy and the Rybelsus and Ozempic pills produced DKK 172.6 billion of the DKK 227.7 billion of adjusted sales, or 76%. The company is Danish, reports in kroner and trades in New York as an ADR that equals one B share.

Two things changed in 2026. First, the US price: Novo struck a pricing deal with the White House in November 2025, and from January 1, 2027 the list price of Wegovy and Ozempic falls to $675 a month, about 50% for Wegovy and 35% for Ozempic. Second, the product: the Wegovy pill launched in January and sold DKK 10.9 billion in nine months, DKK 5.4 billion in the third quarter. US injectable Wegovy sales fell 13% in the quarter at constant rates while combined US Wegovy sales rose 21%, so the pill is replacing injections as much as it is adding patients. At its investor day, the company said self-pay channels are now 50% of the Wegovy franchise, and about 90% of Wegovy pill demand is paid for in cash, which tells you how far pricing has moved from the insurance rebate model.

The latest results

Adjusted operating profit grew 34% in kroner in the quarter, but part of that is an easy comparison: the third quarter of 2025 carried about DKK 9 billion of company-wide restructuring costs, and the third quarter of 2026 carried about DKK 3.5 billion of one-time costs. Reported operating profit fell 3%, because DKK 8.7 billion of non-cash impairments were booked on the heart drug ziltivekimab (DKK 4.6 billion) and on the manufacturing network (DKK 4.1 billion). Reported sales for the nine months include a DKK 26.8 billion reversal of a US rebate provision (the 340B program) in the first quarter, which I exclude by working from adjusted figures.

US Operations returned to growth in the third quarter at +1% at constant rates but are still down 2% for nine months. International Operations grew 8%, and that includes lower prices in markets such as Canada, where semaglutide lost exclusivity and the company says prices fell while volumes held. The adjusted gross margin was 80.3% for nine months and 82.1% in the third quarter; research and development cost DKK 37.0 billion (16% of adjusted sales) and sales and distribution cost fell 13% to DKK 42.1 billion.

The guidance was raised each time: from a decline of 5% to 13% in February, to -6% to 0% in August, to -2% to +2% now. It excludes any new large business development deals. The November free cash flow guide of DKK 60 billion to 70 billion also includes capital spending of about DKK 50 billion, of which DKK 37.2 billion was spent in nine months.

Free cash flow and what it leaves out

Novo's free cash flow is cash from operations (DKK 121.0 billion for nine months) less capital spending on property, plant and equipment (DKK 37.2 billion), which gives the DKK 83.8 billion. The company attributes the strength to phasing of operating expenses, the timing of US rebate and tax payments and lower capital spending. Those are payments postponed, not avoided, so I do not extrapolate the nine months. I use the full-year guide as the 2026 level and check it from the top down.

The top-down figure of DKK 64.5 billion lands within half a billion of the guided midpoint, which gives me some comfort that the guide is a clean number. Capital spending of DKK 50 billion is about 16% of sales and well above depreciation, so much of this is growth investment. I assume the gap narrows from 10.7% of sales to 1.5% by 2036. Stock compensation is small relative to Novo's profits and I have not deducted it separately.

Debt, shares and capital allocation

Net debt is low for a business of this size: DKK 79.7 billion as reported against DKK 125 billion of adjusted operating profit, and about 8% of the market value after my fourth quarter adjustment. Long-term borrowings were DKK 117.7 billion and DKK 16.7 billion falls due within a year. I added the expected fourth quarter outflow because the nine-month cash flow includes liabilities that are still owed. The adjustment is worth $0.64 an ADR.

Shareholders received DKK 61.9 billion in nine months: DKK 51.9 billion of dividends and DKK 10.0 billion of buybacks. The dividend paid over the past twelve months is DKK 11.70 a share (DKK 7.95 in March and DKK 3.75 in August), a yield of 4.3%, before the 27% Danish withholding tax that US holders can partly reclaim. The buyback program is DKK 15 billion; DKK 11.6 billion had been spent by November 2 at an average of DKK 277 a share, a little above today's DKK 271. Dividends of about DKK 52 billion plus DKK 15 billion of buybacks is roughly DKK 67 billion, which is about the whole of guided free cash flow, so there is no room to raise either without borrowing or growth.

Primary valuation: free cash flow through the patent expiry

I project sales, operating margin and reinvestment for ten years. The Base has sales falling 1% in 2027 as the US list price cuts and net price pressure outweigh higher volume, then growing 1% to 4% a year as the pill, CagriSema (the next obesity injection, with a US launch targeted for early 2027 if approved) and other launches add volume. Sales are flat in 2032 and fall 6% in 2033, after the US semaglutide compound patent expires on December 5, 2032 per DelveInsight, and another 2% in 2034. The operating margin goes from 40.7% in 2026 to 38% in 2027 and 37.5% in 2028, back to 39% by 2030, down to 34% in 2034 after the patent expiry, and recovers to 36% by 2036. Free cash flow is taxed at 22%, reinvestment shrinks as the capacity build ends, and the value after 2036 grows at 1.5% with a 15% return on new investment. Cash flows are discounted at 8.5% from the valuation date of November 12, 2026.

The terminal value is 49% of the Base enterprise value (Bear 40%, Bull 53%), well below the 75% level that would need a closer look for a ten year model, because the explicit period is long and already contains the patent cliff. The Base sales rate of 0.7% a year to 2036 is far below the 10% constant-rate growth of 2025, and I chose that on purpose: the guide is flat for 2026, the US price cuts take effect in 2027 and the pill partly cannibalizes injections. The pipeline is inside these paths and not added on top. A 10% pipeline value added to this Base would be double counting.

Sensitivity

The discount rate is the largest judgment. I use one 8.5% rate for kroner cash flows. If you think a lower rate fits better, at 7.5% the Base DCF is $39.02, which is close to the price. One point of margin in every year is worth $1.07 an ADR, and the severity of the 2033 drop is worth $2.93 between no decline and a 12% decline.

Secondary valuation: justified forward earnings multiple

The second method values 2027 adjusted earnings per ADR at a price-to-earnings (P/E) multiple built from the company's own economics instead of from a screener: P/E equals (1 minus growth divided by return on equity) divided by (cost of equity minus growth). It has no view on the 2032 patent expiry beyond the long-run growth rate I put in, so it is a cross-check on the level of earnings power, not on the cliff.

The Base multiple of 13.0 times is a long-run growth rate of 1.5% at a 9% cost of equity. The Bear uses 9 times, which assumes earnings shrink about 2% a year. The Bull uses 15 times. The P/E is applied to my 2027 estimate of $3.00 an ADR (DKK 20.0), which is about 8% below 2026 because of the US price cuts. Each turn of the multiple moves the value by $3.00 an ADR. The Lilly figures come from a single article and one date and bracket the idea that the market pays more for faster growth; they do not set my multiple.

Cross-check against the stock's own range

The 52-week range shown on StockAnalysis at the end of October was $35.12 to $64.16, so the price is 16% above the low and 37% below the high. The shares fell about 18% in Copenhagen on February 4 when the company guided to lower sales and profit, and again on later news. On November 4 the ADR rose 4.95% on the results and gave back 4.46% the next day, so the price is reacting to each guidance change. That makes a value built from cash flow a better anchor than recent trading levels.

Valuation triangulation

The two methods differ by 16.2% at the Base, inside the 20% limit. The Bear gap is 32.9%, which is above 30% and flagged, because the DCF contains the full patent loss and the P/E only sees 2027 earnings. The weights are 60% for the DCF, which sees the cliff, and 40% for the multiple, which anchors the level of profit. They share my 2027 operating profit estimate, so agreement is partly built in.

On a common basis the DCF values the business at 16.5 times 2026 free cash flow and the justified P/E at 19.1 times, against 19.9 times in the market. The probability-weighted value, with 25% Bear, 50% Base and 25% Bull, is $34.45, which is 15.2% below the price. I treat it as a cross-check, not a target.

What is the market already pricing in?

At $40.65 the market wants sales to grow 2.6 points a year faster than my Base for ten years, which is a 3.2% rate, or an operating margin of 46% in 2030, which is above the 41% the company reported for 2025. Each is a single change with everything else at Base. The Bull is a combination of faster growth and a higher margin, and it is worth $46.02 on the DCF, so the price needs most of that case. Equivalently, the price works if the right discount rate is 7.3%.

Bear, base and bull scenarios

• Bear: sales fall 6% in 2027 and 4% in 2028 as US net prices drop faster than volume grows and Lilly keeps taking share, then fall 12% in 2033 and 6% in 2034 after the patent expires. The operating margin drops to 33% by 2029, 27% in 2033 and 26% in 2034. Long-run growth is 0.5%, with a 9 times earnings multiple.
• Base: sales -1% in 2027, then +1%, +3%, +4% and +3%, flat in 2032 and -6% in 2033. The margin holds near 39% through 2031 and falls to 34% in 2034. Long-run growth is 1.5%.
• Bull: sales grow 2% in 2027 and 5% to 6% a year from 2028 to 2031 because the pill and CagriSema take a larger share of obesity, and the cliff costs only 3% in 2033. The margin reaches 42% in 2030 and ends near 40%.

The Bear sits 50% below the price and the Bull 15% above it, so the range leans to the downside. The price needs most of the Bull to deliver a return above 8.5%.

These returns are my arithmetic, not forecasts. They assume all free cash flow, after interest, is returned to shareholders, net debt stays flat and the business is sold at the end of year five at the multiple my own DCF implies for 2031. That multiple is low because the patent expires the following year. The 13.2% in the second row is what you get if investors keep paying today's 19.9 times for a company one year from losing patent protection, which I do not think is a reasonable base case.

How the buy price is set

The required margin of safety follows the confidence grade, and grade C starts at 42.5%. I add nothing on top: the pricing and patent risks are in the scenarios and the sales path, the Bear gap is flagged in the confidence grade, and I do not charge them a second time. $35.50 times 0.575 is $20.41. The two methods give $19.07 and $22.43 separately.

That figure sits close to the Bear value of $20.13, so a purchase there is paid for by the downside case. The stock has not traded that low in the past year (the low was $35.12). If you prefer a return target, the price at which the Base earns 8.5% a year is $34.00 and 10% a year is $32.01.

For an existing holder the price is above the Base, so I would not add. I would review the holding above the Bull value of $46.68, which is 15% higher.

Dividend and buyback

The ADR paid DKK 11.70 a share over twelve months, a 4.3% yield before withholding tax, and the company has restarted its buyback after suspending it in 2025. The company's dividend page shows DKK 11.70 for 2025 (DKK 3.75 interim and DKK 7.95 final), and the interim payment held at DKK 3.75 in 2026. Total cash returns are about the size of free cash flow, so the dividend is covered only while free cash flow holds near DKK 65 billion. In my Base the free cash flow is DKK 66 billion in 2027 and DKK 89 billion in 2030, so the current payout is affordable in the Base. In my Bear it is DKK 60 billion in 2027 and DKK 45 billion in 2033, which would not cover dividends and buybacks together.

Reasons to own Novo Nordisk

• An adjusted gross margin above 80%, an adjusted operating margin of 43% over nine months and a return on invested capital I estimate at about 31% for 2026.
• The Wegovy pill: DKK 5.4 billion in its third quarter on sale, eight markets launched, and the company says it has more than 50% of the branded US obesity market on new patient starts. Eli Lilly's competing pill sold $184 million in the quarter.
• A record of beating its lowered bar: three guidance raises in 2026, sales and distribution costs down 13%, and a free cash flow guide raised from DKK 45-55 billion to DKK 60-70 billion.
• Low debt for the size of the business, with net debt of about 8% of market value.
• Semaglutide keeps US patent protection until December 2032 and the company has several next-generation assets, including CagriSema and oral zenagamtide, entering the final stage of testing.

What could go wrong?

• US pricing: the list price cut on January 1, 2027, the White House pricing agreement, reduced Medicaid coverage and the shift to cash-pay all lower realized prices. The company says the 2027 cash flow will feel the cut, and I take 2027 sales down 1% and operating profit down about 8%.
• Competition: Eli Lilly's tirzepatide has taken the lead in injectable obesity and diabetes sales, and its pill is now on the market. CagriSema delivered 20.2% weight loss against 23.6% for tirzepatide in a head-to-head obesity trial, so it is not clearly ahead of the competition.
• The 2032 patent expiry: the US compound patent runs to December 2032, with possible pediatric extension into 2033. Outside the US, patent expiries in markets including Brazil, Canada and China are already in the 2026 numbers, with lower prices as the first effect.
• Pipeline disappointments: in 2026 the company wrote off ziltivekimab (DKK 4.6 billion), monlunabant (DKK 4.0 billion) and other assets, DKK 15 billion in nine months.
• Cash flow timing: if the fourth quarter outflow is larger than the guide implies, net debt is higher than I assume. DKK 10 billion is worth $0.34 an ADR.
• Control and currency: Novo Holdings, owned by the Novo Nordisk Foundation, holds 28.1% of the shares and 77.3% of the votes. The dollar value of an ADR also moves with the krone: at 7.10 kroner per dollar the Base DCF would be $31.11.
• Valuation of my own numbers: the Base is a top-down path with estimated 2026 profit, depreciation and 2027 onward. It is not a product-by-product forecast.

Management execution

The record is mixed. In 2025 the company cut its guidance several times, changed CEO and booked heavy restructuring costs. In 2026 it has raised the outlook three times, cut sales and distribution costs by 13%, launched the pill ahead of Lilly and restarted the buyback. The same year brought a failed heart drug trial, DKK 15 billion of impairments on pipeline assets and manufacturing, and a US price reset negotiated with the government. Capital spending of about DKK 50 billion is the largest bet on volume I can see. Governance is controlled by a foundation, and proxy adviser ISS has questioned the dual role of the chair, who also leads the Foundation.

Stock Analyza scorecard

Business quality is solid but not top tier. The return on capital is very high at about 31%, but I could document only two years of results in this analysis, so it cannot score the top grade. Pricing power is the weak spot: realized US prices are falling. The balance sheet is strong, though I did not verify the debt maturity schedule or covenants. Earnings quality scores 2 of 4 because reported and adjusted results differ by large one-offs. The growth runway is graded 2 of 4 for three to five years of supported reinvestment, since the US patent ends in 2032.

The valuation score is low because the price is 14.5% above the Base and the Bear is 50% below the price. The third component is an interval because the answer depends on which driver you solve: the price needs more sales growth or a higher margin than the Bull case has in that single driver, yet the Bull as a whole is worth more than the price.

Confidence score

The score rests on the third quarter report, which gives a nearly complete bridge from reported numbers to free cash flow. The gaps are the fourth quarter cash timing, which I infer from guidance, my depreciation estimate, forecasts that are top down rather than by product, and a price I could not check against an independent close. Grade C, with a Bear gap above 30% flagged.

What I would watch from here

The fourth quarter report in early February, with the first 2027 guidance, is the test of how large the price cut really is.

The three most important thesis breakers

1. US net prices fall faster than volume grows, 2027 profit is guided down more than 10% and the Base turns into the Bear.
2. The pill and CagriSema fail to keep the Wegovy share against Lilly, and the 2033 drop is closer to 12% than 6%, which takes $1.47 off the Base DCF by itself.
3. Margins settle one to two points below my Base through the period, which takes about $1 to $2 off the Base DCF (one point is worth $1.07 an ADR).

Stress test and independent check

The model was built from the third quarter 2026 report (6-K), the company's 2025 annual release, the dividend page and ownership data from Novo Holdings and the annual report. The primary value, the secondary value, the triangulation, the buy price, the reverse tests, the sensitivity grids and the returns were recalculated in a separate script, and the numbers in the tables come from that script.

The weakest points are the 2026 adjusted profit and depreciation, which are my estimates inside guidance, the fourth quarter cash timing item, which I infer by subtraction, and the top-down sales path. The conservative choices are a discount rate above what kroner cash flows might justify, a Base sales rate below the company's ambition and a fourth quarter adjustment to net debt. The generous choices are a patent cliff of only 8% over two years and a margin that stays near 35% afterward. I did not use analyst price targets or consensus estimates in the model.

Final verdict: hold at $40.65

Novo Nordisk earns about DKK 65 billion of free cash flow a year on a market value of DKK 1,194 billion and returns almost all of it, which is real. The price after the 2026 recovery pays 19.9 times that cash flow for a business guided flat, with US list prices about to drop and its main patent expiring in six years. The Base earns 4.2% a year, below the 8.5% I require, and a return near 10% needs a purchase at $32.01.

At $40.65 the stock asks you to believe that the price cuts arriving on January 1, 2027 cost less than my model assumes and that the pill replaces the injections it displaces without losing the margin. I allow for both partly, and that leaves about $36.

Verdict: HOLD at $40.65, watchlist for new money. Base $35.50, -12.7% against the price, Bear $20.13, Bull $46.68, Confidence C (15/25). Required margin of safety 42.5%, maximum buy price $20.41, range $19.07 to $22.43 under the two methods.

The buy zone can come to the stock in two ways: a price near $20.41, or evidence that the 2027 profit decline is smaller than 5% and the pill is adding volume without cutting margin, which would lift the Base. The 2027 guidance in February is the first data point.

Sources

Primary sources are Novo Nordisk's financial report for the first nine months of 2026 (6-K, November 4, 2026), the company announcement, the 2025 annual release and the dividend page. Ownership and votes come from Novo Nordisk's annual report.

Context and third-party data: Reuters via TimesLIVE (third guidance raise, US Wegovy sales), StockAnalysis (earlier free cash flow guide, Lilly pill sales), Pharmaceutical Technology (February guidance and share price reaction), DelveInsight (US semaglutide patent date), Finimize (investor day and self-pay mix), TIKR (Eli Lilly multiple) and Bloomberg Tax (ISS comment on the chair) and Rallies (CagriSema head-to-head result).

Prices and rates: the XTB quote of $40.65, the StockAnalysis price history (latest close available to me was $40.31 on November 6) and the 52-week range from StockAnalysis, and the November 10 exchange rate from moneyexchangerate.org.